Proteonomix, Inc. (PROT) Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease
(firmenpresse) - MOUNTAINSIDE, NJ -- (Marketwire) -- 01/04/12 -- Proteonomix, Inc. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Company's clinical trial of UMK-121 has received IRB (Institutional Review Board) approval and is now ready for the recruitment of patients.
We thank the University of Miami once more for providing the IRB and their invaluable contribution to this study of the UMK-121 drug therapy on patients with End Stage Liver Disease.
To better understand what a clinical trial is and the expenses associated with clinical trials please visit the following links: ; ; .
As previously announced, the Company entered into an Agreement to conduct the clinical trial with the That Agreement required the University to pay expenses associated with the clinical study and The Company was required to assist financially with the clinical study which the Company has done.
Michael Cohen, President of the Company, stated: "The financing that was required to complete the Company's obligation with respect to the Trial was provided Friday, December 23, 2011. The Company will work together with the University and the principal investigators to initiate the clinical study. The approval of the IRB was required before the study could go forward. The investigators can now accept patients into the study."
About Proteonomix, Inc.:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix Family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit , , and .
Forward-looking statements:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.
Contact:
Proteonomix, Inc.
Michael Cohen
CEO
Phone: +1-973-544-6116
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.01.2012 - 08:00 Uhr
Sprache: Deutsch
News-ID 1069821
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MOUNTAINSIDE, NJ
Phone:
Kategorie:
Alternative
Anmerkungen:
Diese Pressemitteilung wurde bisher 155 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Proteonomix, Inc. (PROT) Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients With End Stage Liver Disease
"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteonomix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
